Conversely, increased BTN3A2 expression was associated with increased risk of inflammatory bowel disease (IBD; 0.025), including Crohn’s disease (0.053), as well as risk of PBC (0.129), where PBC variants also showed colocalisation with BTN3A2 eQTLs (Fig. 4, Supplementary Fig. 12). Here, BTN3A2 is linked to inflammatory bowel disease.